Information sur le laboratoire
Peter Lakatos (M.D.)
ChercheurUnité de recherche clinique
Département de médecine (McGill)
Profil de recherche
Mots-clés
Maladie inflammatoire des intestins (MICI) • gastroentérologie • colite • maladie de CrohnMembre de l'équipe
| Nom | Poste |
|---|
Dernières publications
- Farkas, B., Bessissow, T., Limdi, J. K., Sethi-Arora, K., Kagramanova, A., Knyazev, O., Bezzio, C., Armuzzi, A., Lukas, M., Michalopoulos, G., Chaskova, E., Savarino, E. V., Castiglione, F., Rispo, A., Schäfer, E., Saibeni, S., Filip, R., Attauabi, M., Fousekis, F. S., Bacsur, P., Resál, T., Bálint, A., Ivány, E., Szepes, Z., Bősze, Z., Fábián, A., Bor, R., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study. Journal of clinical medicine, vol. 13.
- Di Fonzo, D. M. P., Alabdulkarim, B., Yanofsky, R., Abduallah, Y., Golovics, P., Lakatos, P. L., Bitton, A., Wild, G., Afif, W. & Bessissow, T. (2024). Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn's Disease Patients. Crohn's & colitis 360, vol. 6, p. otae071.
- Wetwittayakhlang, P. & Lakatos, P. L. (2024). Advanced combination therapy: is it the best way to break the therapeutic ceiling?. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241272995.
- Abbas, A., Di Fonzo, D. M. P., Wetwittayakhlang, P., Al-Jabri, R., Lakatos, P. L. & Bessissow, T. (2024). Management of ulcerative colitis: where are we at and where are we heading?. Expert review of gastroenterology & hepatology, p. 1-8.
- Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241290636.
- Lalani, S., Mathias, H., Heisler, C., Rohatinsky, N., Mirza, R. M., Kits, O., Zelinsky, S., Nguyen, G., Lakatos, P. L., Fowler, S., Rioux, K. & Jones, J. L. (2024). Improving access to inflammatory bowel disease care in Canada: The patient experience. Journal of health services research & policy, p. 13558196241276979.
- Angyal, M. M., Janssen, M. F., Lakatos, P. L., Brodszky, V. & Rencz, F. (2024). The added value of the cognition, dining, gastrointestinal problems, sleep and tiredness bolt-on dimensions to the EQ-5D-5L in patients with coeliac disease. The European journal of health economics : HEPAC : health economics in prevention and care.
- Shehab, M., De Marco, D., Lakatos, P. L. & Bessissow, T. (2024). The potential for medical therapies to address fistulizing Crohn's disease: a state-of-the-art review. Expert opinion on biological therapy, p. 1-14.
- Barkai, L. J., Gonczi, L., Balogh, F., Angyal, D., Farkas, K., Farkas, B., Molnar, T., Szamosi, T., Schafer, E., Golovics, P. A., Juhasz, M., Patai, A., Vincze, A., Sarlos, P., Farkas, A., Dubravcsik, Z., Toth, T. G., Szekely, H., Miheller, P., Lakatos, P. L. & Ilias, A. (2024). Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years. Scientific reports, vol. 14, p. 14909.
- Pattarapuntakul, T., Wong, T., Wetwittayakhlang, P., Netinatsunton, N., Keeratichananont, S., Kaewdech, A., Jandee, S., Chamroonkul, N., Sripongpun, P. & Lakatos, P. L. (2024). Efficacy of Vonoprazan vs. Intravenous Proton Pump Inhibitor in Prevention of Re-Bleeding of High-Risk Peptic Ulcers: A Randomized Controlled Pilot Study. Journal of clinical medicine, vol. 13.
Voir aussi
